1620 Investment Advisors’s TG Therapeutics TGTX Stock Holding History

1620 Investment Advisors’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$205K	Sell	3,735 -181	-5%	-$7.41K	0.13%	178
2026 Q1	$130K	Sell	3,916 -53	-1%	-$1.58K	0.09%	204
2025 Q4	$118K	Buy	3,969 +40	+1%	+$1.31K	0.08%	213
2025 Q3	$142K	Sell	3,929 -166	-4%	-$5.47K	0.1%	184
2025 Q2	$147K	Sell	4,095 -107	-3%	-$3.98K	0.1%	181
2025 Q1	$166K	Sell	4,202 -55	-1%	-$1.85K	0.13%	160
2024 Q4	$128K	Buy	+4,257	New	+$122K	0.1%	189

Other funds holding TGTX

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

SOADOR

State of Alaska Department of Revenue Juneau, Alaska $10.1B AUM 42.83% 1-Year Est. Return

LSERS

Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

PFSRSONJ

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

YCM

Yousif Capital Management Bloomfield Hills, Michigan $8.94B AUM 42.6% 1-Year Est. Return

TAM

Tealwood Asset Management Minneapolis, Minnesota $261M AUM 52.68% 1-Year Est. Return

1620 Investment Advisors's TGTX Position: Q2 2026 in Review

1620 Investment Advisors reduced its TG Therapeutics (TGTX) stake by 4.6% in Q2 2026, selling an estimated $7.41K and leaving 3,735 shares worth $205K. The position accounts for 0.13% of the portfolio, ranked #178.

1620 Investment Advisors first reported a position in TGTX in Q4 2024 and has held it in 7 quarters since. 103 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

1620 Investment Advisors held 3,735 shares of TG Therapeutics worth $205K as of Q2 2026.
1620 Investment Advisors sold 181 TG Therapeutics shares in Q2 2026, an estimated $7.41K.
TG Therapeutics made up 0.13% of 1620 Investment Advisors's portfolio in Q2 2026, its #178 holding.
1620 Investment Advisors first reported a position in TG Therapeutics in Q4 2024 and has held it in 7 quarters since.
103 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on 1620 Investment Advisors's 13F filing for Q2 2026, filed 14 Jul 2026.